MGMT Promoter Methylation

CI-VAR-00003475Explore in graph →CIViC 85

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Glioblastoma6
MGMT Promoter Methylation	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID172 MGMT promoter methylation was associated with increased overall and disease-free survival as well as tumor regression in patients with gliomas. PMID 11070098 · Esteller et al., 2000 · Open in CIViC	civic
MGMT Promoter Methylation	(prognostic)	Prognostic	B	Supports Better Outcome	5	accepted	EID491 In patients with glioblastoma, those with methylated MGMT promoters have better overall survival than those with unmethylated promoters. PMID 15758010 · Hegi et al., 2005 · Open in CIViC	civic
MGMT Promoter Methylation	Carmustine	Predictive

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Oligodendroglioma1
MGMT Promoter Methylation	(prognostic)	Prognostic	B	Supports Better Outcome	4	accepted	EID490 In a study of 152 anaplastic oligodendroglial tumors, 121 samples had MGMT promoter methylation. Those with promoter methylation had better progression-free and overall survival. PMID 19901104 · van den Bent et al., 2009 · Open in CIViC	civic